Innate Immunotherapeutics Ltd (IIL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Innate Immunotherapeutics Ltd (IIL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013225
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innate Immunotherapeutics Ltd (Innate Immunotherapeutics), formerly Innate Therapeutics Ltd is a medical biotechnology company that develops therapeutic drugs for the treatment of cancer and infectious diseases. The company designs and develops immunomodulator microparticle technology. Innate Immunotherapeutics’ lead drug candidate MIS416 is a microparticle and non-immunogenic, cytosolically-active TLR-9 and NOD-2 ligands, which is used for cancer therapy and acts as an anti-metastatic agent. The company uses microparticle platform technology that induces the human immune system to fight against various cancers and infections; and to design preventive vaccines for influenza, cancer, malaria, or tuberculosis. The company offers products and services to treat auto-immune diseases and infectious diseases. It has operations in Australia and New Zealand. Innate Immunotherapeutics is headquartered in Sydney, New South Wales, Australia.

Innate Immunotherapeutics Ltd (IIL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 10
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 13
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 15
Innate Immunotherapeutics Completes IPO For US$9 Million 16
Innate Immunotherapeutics Announces Public Offering Of Shares For US$10 Million 18
Innate Immunotherapeutics Ltd – Key Competitors 19
Innate Immunotherapeutics Ltd – Key Employees 20
Innate Immunotherapeutics Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Other Significant Developments 22
Oct 30, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 22
Jul 28, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Innate Immunotherapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 10
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 13
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 15
Innate Immunotherapeutics Completes IPO For US$9 Million 16
Innate Immunotherapeutics Announces Public Offering Of Shares For US$10 Million 18
Innate Immunotherapeutics Ltd, Key Competitors 19
Innate Immunotherapeutics Ltd, Key Employees 20
Innate Immunotherapeutics Ltd, Other Locations 21

★海外企業調査レポート[Innate Immunotherapeutics Ltd (IIL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sc Arcada Con Srl:企業の戦略的SWOT分析
    Sc Arcada Con Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Galectin Therapeutics Inc (GALT):医療機器:M&Aディール及び事業提携情報
    Summary Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company provides products such as GR-MD-02, GM-CT-01, and others. Its GR-MD-02 is a drug c …
  • Accenture plc:企業の戦略・SWOT・財務分析
    Accenture plc - Strategy, SWOT and Corporate Finance Report Summary Accenture plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Jordan Trade Facilities Company PLC (JOTF):企業の財務・戦略的SWOT分析
    Jordan Trade Facilities Company PLC (JOTF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Neograft Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Neograft Technologies Inc (Neograft) is a medical device company that cardiac technologies for use in heart bypass procedures. The company offers solutions such as saphenous vein harvesting, coronary artery bypass graft, and others. It develops and provides angioshield, which is a transforma …
  • STR Holdings Inc:企業の戦略的SWOT分析
    STR Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Anavex Life Sciences Corp (AVXL):企業の財務・戦略的SWOT分析
    Anavex Life Sciences Corp (AVXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ferring International Center SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (foll …
  • Second Sight Medical Products Inc (EYES):企業の財務・戦略的SWOT分析
    Summary Second Sight Medical Products Inc (Second Sight) is a medical device company that develops, manufactures and markets implantable visual prosthetics for blind individuals. The company offers Argus II retinal prosthesis system, a device that restores some functional vision for people suffering …
  • TV Asahi Corporation (9409):企業の財務・戦略的SWOT分析
    TV Asahi Corporation (9409) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bank of Singapore Ltd.:企業の戦略・SWOT・財務情報
    Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • WuXi NextCODE Genomics:医療機器:M&Aディール及び事業提携情報
    Summary WuXi NextCODE Genomics USA Inc (WuXi NextCODE), a subsidiary of Wuxi Pharmatech (Cayman) Inc, is a genomic information company that offers competencies in generating, organizing, mining, sharing and applying genomic data. The company develops gene sequence analysis platform and database arch …
  • SARIA AS GmbH & Co KG:企業の戦略的SWOT分析
    SARIA AS GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Memphasys Ltd (MEM):医療機器:M&Aディール及び事業提携情報
    Summary Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd, is a bio-separations company that develops and commercializes membrane technology solutions. The company develops felix, a non-DNA damaging lab instrument for sperm separation that separates sperm from semen sample using electrophoresis …
  • CGU Insurance Ltd:企業の戦略・SWOT・財務分析
    CGU Insurance Ltd - Strategy, SWOT and Corporate Finance Report Summary CGU Insurance Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • TriMedx LLC:企業の戦略的SWOT分析
    TriMedx LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Galena Biopharma Inc (GALE)-医療機器分野:企業M&A・提携分析
    Summary Galena Biopharma Inc (Galena) is a biopharmaceutical company that develops and markets therapies for the treatment of unmet medical needs and advance care. The company's pipeline products comprise NeuVax, NeuVax Present, NeuVax Hercepti, NeuVax Vadis, GALE-401 and GALE-301 folate binding pro …
  • Global Sweeteners Holdings Ltd (03889):企業の財務・戦略的SWOT分析
    Global Sweeteners Holdings Ltd (03889) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Kenzo Parfums NA, LLC:企業の戦略・SWOT・財務情報
    Kenzo Parfums NA, LLC - Strategy, SWOT and Corporate Finance Report Summary Kenzo Parfums NA, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • South Carolina Electric & Gas Company:電力:M&Aディール及び事業提携情報
    Summary South Carolina Electric & Gas Company (SCE&G), a subsidiary of Scana Corporation, is an energy utility that generates, transmits, distributes and trades of electricity; and purchases, transports and sells natural gas. The company generates electricity through diverse energy sources such as n …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆